Graphite Bio Top Insiders
GRPHDelisted Stock | USD 2.67 0.05 1.84% |
Graphite Bio employs about 6 people. The company is managed by 11 executives with a total tenure of roughly 14 years, averaging almost 1.0 years of service per executive, having 0.55 employees per reported executive. Assessment of Graphite Bio's management performance can provide insight into the firm performance.
Graphite |
Graphite Bio Management Team Effectiveness
The company has return on total asset (ROA) of (0.1799) % which means that it has lost $0.1799 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5195) %, meaning that it created substantial loss on money invested by shareholders. Graphite Bio's management efficiency ratios could be used to measure how well Graphite Bio manages its routine affairs as well as how well it operates its assets and liabilities.Graphite Bio Workforce Comparison
Graphite Bio is rated below average in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 773. Graphite Bio maintains roughly 6.0 in number of employees contributing less than 1% to equities under Health Care industry.
Graphite Bio Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Graphite Bio insiders, such as employees or executives, is commonly permitted as long as it does not rely on Graphite Bio's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Graphite Bio insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Stultz Katherine V over six months ago Conversion by Stultz Katherine V of 8126 shares of Graphite Bio | ||
Jerel Davis over a year ago Acquisition by Jerel Davis of 20000 shares of Graphite Bio subject to Rule 16b-3 |
Graphite Bio Notable Stakeholders
A Graphite Bio stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Graphite Bio often face trade-offs trying to please all of them. Graphite Bio's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Graphite Bio's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Kimberlee CPA | CEO and Presidentident | Profile | |
Stephanie Yao | Vice Relations | Profile | |
Maria MD | Academic Board | Profile | |
Christine PMP | Chief Operations | Profile | |
Jerry Cacia | Chief Officer | Profile | |
Philip Gutry | Chief Officer | Profile | |
Jane Grogan | Chief Officer | Profile | |
MD FACC | CEO Pres | Profile | |
Daniel Dever | CoFounder Research | Profile | |
Alethia Young | Chief Officer | Profile | |
Matthew MD | Academic Director | Profile |
About Graphite Bio Management Performance
The success or failure of an entity such as Graphite Bio often depends on how effective the management is. Graphite Bio management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Graphite management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Graphite management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Graphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States. Graphite Bio, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California. Graphite Bio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 111 people.
Graphite Bio Workforce Analysis
Traditionally, organizations such as Graphite Bio use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Graphite Bio within its industry.Graphite Bio Manpower Efficiency
Return on Graphite Bio Manpower
Revenue Per Employee | 0.0 | |
Revenue Per Executive | 0.0 | |
Net Loss Per Employee | 20.8M | |
Net Loss Per Executive | 11.3M | |
Working Capital Per Employee | 30.5M | |
Working Capital Per Executive | 16.7M |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Other Consideration for investing in Graphite Stock
If you are still planning to invest in Graphite Bio check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Graphite Bio's history and understand the potential risks before investing.
Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
Money Managers Screen money managers from public funds and ETFs managed around the world | |
Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
FinTech Suite Use AI to screen and filter profitable investment opportunities | |
Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios |